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Summary
The results o f fibrinolytic therapy with urokinase were evaluated in 
26 neonates with catheter related central venous thrombosis. Complete 
thrombolysis could be achieved in 13 patients (50%), partial thrombo­
lysis in 3 patients (12%). No effect was seen in 10 patients (38%). 
Therapy success was influenced by age, size and location of the throm­
bus. Coincidence of infection occurred in 16 patients (62%), Mild 
hemorrhagic complications were seen in 2 patients (8%), no other 
significant side effects were observed, Nine patients with residual 
thrombosis were treated with oral anticoagulants following urokinase 
resulting in resolution of the thrombus in 6 patients within 3 months 
(67%). The incidence of asymptomatic recurrent thrombosis was high 
(28%). Urokinase might be an effective and safe treatment for central 
venous thrombosis in neonates. Prophylactic antibiotic therapy during 
the infusion of urokinase and long-term treatment with oral anticoagu­
lants after thrombosis are advisable, Early detection of thrombosis 
might enhance the success rate of fibrinolytic therapy. Therefore, 
we strongly recommend routine echocardiographic screening of central 
venous catheters.
>•
*
introduction
The use of central venous catheters to optimize nutrition and moni­
toring of low birth weight and critically ill newborns has become com­
mon practice in neonatal intensive care units. However, these catheters 
are not without potential hazards. Sepsis and thrombosis are known ma­
jor complications (1—4). Central venous thrombosis can be associated 
with significant morbidity and mortality. Early detection and treatment 
is crucial.
There is no consensus in the literature about the treatment of choice 
for neonates with central venous thrombosis. Immediate removal of the 
catheter, once the diagnosis of central venous thrombosis is made, has 
been recommended (5). However, the risk for pulmonary embolization 
due to mobilization of the thrombus is imaginable. Surgical thrombec­
tomy is technically difficult and poses a considerable life threatening 
risk to the severely ill infant (6-8). Heparin is a prophylactic drug and 
could be used in patients with mild thrombosis to prevent further 
thrombus extension. Nevertheless, one should not rely exclusively on 
the endogenous fibrinolytic capacity of the neonate, but should attempt 
to lyse a major central venous thrombus with thrombolytic agents (9).
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In the past decade thrombolytic drugs have gained widespread recogni­
tion in the treatment of myocardial infarction, pulmonary embolism, 
deep venous and arterial thrombosis (10,11). Although used extensive­
ly in the adult, there is sparse information on their effectiveness in the 
newborn (6). There have been no large case-series or controlled trials of 
infants treated with fibrinolytic agents for catheter related thrombosis. 
Eight case reports describe the use of urokinase in neonates, using dif­
ferent dosages and therapy durations (12-19). These initial successful 
reports regarding thrombolytic therapy in neonates encouraged us to 
apply this therapy to our patients. In this report, we present our experi­
ence of 26 infants treated with urokinase infusion for catheter related 
central venous thrombosis.
Patients and Methods
Between October 1988 and September 1992, at our neonatal intensive care 
unit, central venous catheters were inserted in 434 infants. All patients with 
central venous catheters were traced by analysis of our computerized registra­
tion. The catheters used were either polyvinylchloride umbilical catheters 
(Sherwood®, Argyle), hydrophilic polyurethane catheters (Hydrocalh® or Um- 
bilicath®, Viggo) or silastic catheters (Broviac®, Bard). Venous access was 
achieved by means of umbilical vein catheterization in 216 patients (50%). In 
the remaining 218 infants (50%) catheters were placed either by means of per­
cutaneous insertion via peripheral veins (basilic vein, greater saphenous vein, 
cephalic vein) or via the subclavian vein using the Seldinger method on the 
ward (20), or through cutdown of the jugular vein in the operating room. Right 
atrial position of the catheter tip was confirmed by chest X-ray. Heparin was in­
fused at a continuous rate of 2 U/h through the catheters. A continuous mini­
mum flow of 2 ml/li of dextrose solution was maintained through the catheters 
at all times. The central venous catheters were not used for infusion of packed 
red blood cells nor to obtain blood samples, except blood cultures in case of 
clinical suspicion of sepsis. Sepsis was suspected if two or more of the fol­
lowing clinical signs were present: leucopenia <5.0 X 109/1, C-reactive protein 
>20 mg/1, deterioration of respiratory and/or circulatory functions, temperature 
instability. Infection was defined as a positive blood culture drawn through the 
central venous catheter and/or a positive culture of the tip of the catheter after 
removal. Sepsis was defined as positi ve cultures with clinical signs of sepsis.
Since September 1989 echo Doppler cardiography has been performed as 
routine screening in all patients with central venous catheters before removal of 
the catheter or sooner in case of symptoms of thrombosis. Before this data echo 
Doppler cardiography was only performed on indication. A thrombus was de­
fined as an echodense structure larger than 2 mm in the heart or in the great 
vessels. Special attention was paid to the superior and inferior vena cava, the 
hepatic vein and to malposition of the catheter in the left atrium. Length and 
diameter of the thrombus were measured in mm, thrombus mass was calculated 
in mm3 (^ rr21, whereas r -  radius and 1 = length of the thrombus). Echo Dopp­
ler cardiography led to the diagnosis in 23 patients (Fig. 1). Some peripheral 
veins (subclavian vein, hepatic vein) are easier visualized by catheter phle­
bography, which was used in 3 patients to confirm the diagnosis.
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All 26 patients (14 girls and 12 boys) with catheter related central venous 
thrombosis were treated with urokinase. The records, echo Doppler cardiog­
raphy reports and laboratory values of these patients were reviewed. None of 
the patients had a platelet count below 50 X 10IJ/1 or a history of intracranial 
hemorrhage (21),
Immediately after establishing the diagnosis, blood samples were taken for 
determination of thrombin time, fibrinogen and plasminogen as a baseline 
before urokinase infusion. In an attempt to reach an effective local thromboly­
sis the catheter was left in place and used for urokinase administration. Uro­
kinase was given as a bolus of 44001U per kilogram of body weight over
10 minutes, followed by a continuous initial infusion of 4400IU per kilogram 
per hour (6, 10). No other antithrombotic agents were used concurrent with 
urokinase. The prophylactic infusion of heparin 2 U/h was interrupted during 
urokinase therapy. After urokinase administration, thrombin time and fibrino­
gen were measured at intervals of 4 h during the first 12 h and thereafter once 
every 12 h if necessary. In order to achieve a safe fibrinolytic state the uroki­
nase infusion rate was adjusted until the thrombin time was prolonged to 2-3 
times normal control values (50-75 s) (10). Whenever the fibrinogen level 
dropped below 1000 mg/1 (6), fresh frozen plasma was administered in a dose 
of 10 ml per kilogram of body weight while thrombolytic therapy was contin­
ued. Careful clinical observation, monitoring of vital parameters and cerebral 
ultrasound were performed to detect hemorrhage. If any signs of bleeding 
occurred urokinase was stopped instantly. After three days of treatment echo- 
cardiographic assessment was repeated to evaluate therapy success, if neces­
sary, remaining thrombus mass was calculated. A complete resolution of the 
thrombus was considered successful thrombolysis. In cases of partial thrombus 
reduction therapy was continued for another 2 to 3 days. If the clot resolved 
completely or if the clot still persisted despite extended therapy the urokinase 
infusion was terminated and the catheter was removed. After removal the tip of 
the catheter was cut off in a sterile manner and cultured.
Immediately following urokinase therapy oral anticoagulants were started in 
patients with residual thrombosis, in order to prevent thrombus extension and 
possibly enhance further resolution of the thrombus. In patients without resid­
ual thrombosis oral anticoagulants were only prescribed if the thrombus had 
been echographically adherent to the atrium or vessel wall, in which case there 
is an increased risk of damage to the endothelium and subsequent recurrent 
thrombosis. Fenprocoumon was used in the period 1988-1990, in a dose of 
200-300 jjLg/kg. Since 1991, we used warfarin in an initial dose of 200 to 
400 jxg/kg, followed the next day by a maintenance dose of 50-200 jig/kg' 
once a day. The dose was adjusted until thrombotest values were reached be­
tween 2.5-33 INR. Treatment with oral anticoagulants was supported by low 
dose urokinase (100-400 U/kg per hour) to ensure vessel patency until 
adequate thrombotest values were reached. Duration of treatment with oral 
anticoagulants was 3 months, after which period follow-up echo Doppler 
cardiography was performed.
For all data, means and standard deviations were calculated. Statistical ana­
lysis was performed where necessary using the Chi-square test, Wilcoxon test 
or Student-t-test. Results were considered to be significant when p <0.05.
Results
Characteristics of 26 neonates with central venous thrombosis are 
presented in Table 1. The remaining 408 patients without central ve­
nous thrombosis had a mean birth weight of 1988 ± 1041 grams and a 
mean gestational age of 33.5 ±5 .0  weeks. Both birth weight and gesta­
tional age were significantly higher in the group with thrombosis 
(p <0.05 and p <0.02).
Among the 26 patients with catheter related central venous throm­
bosis prematurity (n = 8) and birth asphyxia (n = 7) were the main rea­
sons for admission to our department. Less frequent diagnoses were 
congenital diaphragmatic hernia (n = 3), meconium aspiration syn­
drome (n = 2), sepsis (n = 2), gastro-intestinal surgery (n = 2), pneumo­
thorax (n = 1) and chylothorax (n = 1). All patients were critically ill on 
admission, 24 required artificial ventilation, All patients received total
Fig. I Two-dimensional echocardiogram showing a large thrombotic mass in 
the right atrium (RA). LA: left atrium, RV: right ventricle, LV; left ventricle
parenteral nutrition and multiple medications through their central 
venous catheters. The osmolality of the infused solutions ranged from 
285 to 750 mOsm/l.
Half of the central venous catheters were inserted within the first two 
days of life. Umbilical vein catheterization was performed in 14 pa­
tients. The percutaneous method via peripheral veins was applied in 
4 patients. In 5 patients venous access was achieved by means of 
percutaneous catheterization of the subclavian vein and in 3 patients 
by means of cutdown of the jugular vein. Catheters used were 
Polyvinylchloride umbilical catheters 5 French (n = 5), hydrophilic 
polyurethane umbilical catheters 5 French (n = 7), single lumen hydro­
philic percutaneous catheters 22 or 20 Gauge (n = 7), double lumen 
hydrophilic polyurethane percutaneous catheters 18 Gauge (n = 3), and 
silastic catheters 4.2 French (n = 3). In one patient the type of the 
catheter was unknown.
At the time of diagnosis 15 patients (58%) had clinical symptoms 
suspicious for central venous thrombosis, particularly sepsis (n = 14), 
sometimes in combination with superior or inferior vena cava syn­
drome (n = 8) and/or chylothorax (n = 1). The remaining 11 patients 
(42%) had no clinical symptoms of thrombosis at the time of diagnosis, 
except signs of catheter malfunction such as partial or complete occlu­
sion (n = 2).
Table I Patient characteristics (n = 26)
Mean SD Range
General
Gestational age (weeks) 36.1 4.8 26.9-42.0
Birthweiglit (grams) 2603 1350 495-4580
Apgar score 5’ 6.8 2.4 3.0-10.0
Thrombus
Age at diagnosis (days) 19 15 5-56
Indwelling time catheter (days) 13 9 4-50
Thrombus mass (mm3) 263 352 4-1649
Coagulation studies
Thrombin time (s) 38 6 28-54
Fibrinogen (ml/1) 3470 1248 1410-5789
Plasminogen (%) 66 15 44-91
Urokinase
Max. maintenance (U/kg X h) 14345 9105 4400-35700
Therapy duration (h) 92 51 21-262
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Fig. 2 Mean thrombin time values and 
96 mean fibrinogen levels with standard devia­
tions during urokinase therapy
182
Positive blood or catheter tip cultures were found in 16 patients 
(62%). Eleven of these patients also had clinical signs of sepsis. The in­
fections were predominantly caused by Staphylococcus epidermidis 
(n = 9). Other cultured micro-organisms included: Staphylococcus 
aureus (n = 2); Escherichia coli (n = 2); Enterobacter cloacae (n = 2); 
Klebsiella oxytoca (n = 1). The occurrence of infection seemed to be in­
fluenced by the indwelling time of the catheter: a mean indwelling time 
of 15 days in patients with infection, and a mean indwelling time of 
10 days in patients without infection. The difference was not statisti­
cally significant.
In 10 patients the thrombus was located in the right atrium (38%). 
Other locations included: superior vena cava (n = 5); inferior vena cava 
(n = 2); left atrium (n = 3); hepatic vein (n = 4); subclavian vein (n = 2). 
Thrombosis in the left atrium could be explained by malposition of the 
central venous catheter with crossing of the foramen ovale. Mean 
thrombus size at the time of diagnosis was 263 mm3.
Coagulation studies before therapy and average urokinase dosage 
are listed in Table 1 > Average thrombin time and fibrinogen course dur­
ing urokinase therapy are mapped out in Fig. 2. In 19 patients a throm­
bin time > 5 0  s was achieved. In 9 patients fibrinogen dropped below 
1000 mg/1 and fresh frozen plasma was administered during urokinase 
infusion. Neither the maximum thrombin time nor the administration of 
fresh frozen plasma correlated with therapy success.
Complete thrombolysis was achieved in 13 patients (50%). In these 
patients there was no residual thrombus detectable by echo Dopier car­
diography after urokinase therapy, indicating a thrombus mass reduc­
tion of 100%. Partial thrombolysis could be achieved in 3 patients 
(12%). These patients presented a reduction in thrombus mass of 64%, 
61% and 20% respectively. Of the remaining 10 patients (38%) the 
thrombus did not change or became even larger despite urokinase thera­
py. Hence, therapy failure was observed in a total of 13 patients (50%). 
In one patient an extremely large thrombus extended through the for­
amen ovale into the left atrium, necessitating surgical thrombectomy 
to prevent cerebral thromboembolic complications. Several factors 
influencing therapy success of urokinase are presented in Table 2*
Mild hemorrhagic complications were noted in 2 patients. In these 
cases therapy was stopped because of persistent oozing from previous 
heel puncture sites and a dropping hemoglobin level. Both patients had 
a fibrinogen level below 1000 mg/1 before the onset of hemorrhagic 
complications. The remaining 7 patients with fibrinogen levels below 
1000 mg/1 (lowest value 215 mg/1) did not have any signs of bleeding. 
Cerebral hemorrhage or focal ischemic cerebral damage due to embolic 
complications were excluded in our patients by means of ultrasound 
examination.
Table 2 Factors influencing therapy success of urokinase
Patients Success (%)
Indwelling time catheter
< 14 days 19 11 (58%)
^14 days 7 2 (29%)
Thrombus size
< 100 mm3 7 5 (71%)
s i  00 mm3 14 5 (36%)
Thrombus localization
central 20 12 (60%)
peripheral 6 1 (17%)
Blood culture
negative 10 7 (70%)
positive 16 6 (38%)
Perinatal asphyxia
Apgar 5’ >7 11 7 (64%)
Apgar5’ <7 15 4 (27%)
no rethrombosis: 1 rethrombosis; 3 rethrombosis: 1 resolved: 6 unknown: 2
,__________ I I T
unknown; 5 no rethrombosis: 1 persisting: 3 persisting: 1
unknown: 3
Fig. 3 Overview of outcome and after treatment of 26 patients treated with 
urokinase for central venous thrombosis. OAC: oral anticoagulants
especially silastic catheters has been reported by several authors (2,16, 
23). The incidence of central venous thrombosis in our department was 
6%. Due to the lack of routine screening of central venous catheters 
during the first year of our study period, and the fact that catheter 
phlebography was not performed systematically in our patients an 
underestimation of the incidence of thrombosis may be possible.
Thrombosis on the tip of a central venous catheter can cause ob-
Of 12 patients with residual thrombosis 9 received additional struction and catheter malfunction and subsequent stasis of blood and 
treatment with oral anticoagulants (Fig. 3). In six of these patients the solutions (13). Superimposed infection with bacteria or fungi easily 
treated residual clots resolved within 3 months* Two patients with occurs and can lead to life-threatening illness (22, 24). Right atrial 
residual thrombosis died of severe bronchopulmonary dysplasia and thrombi may obstruct venous return which can lead to superior or infe- 
sepsis before oral medication was tolerated, and in one patient a rior vena cava syndrome, hydrocephalus, or chylothorax (22, 25, 26). 
contraindication for oral anticoagulants was present. Of 14 patients When the thrombus extends through the tricuspid valve into the right 
without residual thrombosis after urokinase therapy or thrombectomy ventricle tricuspid insufficiency may incite cardiac failure (12, 27). If 
7 received oral anticoagulants. At follow-up ultrasound asymptomatic clot disruption occurs, irreversible vascular obstructive disease may re­
recurrent thromboses were noted in 4 of 14 successfully treated pa- suit from multiple small micro-emboli in the pulmonary vasculature.
tients, 3 despite additional oral anticoagulants.
Discussion
Cardiac arrest and death due to major pulmonary embolism have been 
reported (16 ,22 ,27 ). Cerebral emboli are also possible in cases of left 
atrial thrombi (27). We noted several of these complications in our 
patients, particularly infection and vena cava syndrome. Nevertheless,
Central venous thrombosis has been reported to occur in 2-10%  as much as 35% of our patients remained asymptomatic.
of neonates with central venous catheters (3, 4 ,13 , 22). An increased Prevention of these harmful complications by early detection of
incidence of thrombosis (up to 25%) with the use of larger catheters, thrombosis is essential. Echo Doppler cardiography or catheter phle-
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bography are most frequently applied for this purpose. Echo Doppler 
cardiography allows visualization and accurate localization and meas­
urement of a thrombus in the heart or great vessels. Modern ultrasound 
technology makes it possible to distinguish distances of less than 1 mm 
(28). However, in neonates the diagnostic efficacy of echocardiography 
for the detection of venous thrombosis has not been adequately as­
sessed (29). Also, echo Doppler cardiography can not provide sufficient 
assessment to thrombosis in peripheral veins. Therefore, studies com­
paring echo Doppler cardiography and catheter phlebography in neo­
nates are urgently needed. The importance of routine screening for throm­
bosis has been emphasized in the literature. It has been recommended 
that the initial investigation should be obtained no sooner than 3 weeks 
after catheter insertion (3). Nevertheless, in our study 19 (73%) throm­
bi were detected at a catheter indwelling time of less than 14 days, in­
dicating that the initial screen should be obtained before the second 
week.
significant differences can not be proved. Rather large differences are 
required to obtain statistical significance. Nevertheless, these results 
could provide some guidelines for future investigations in neonates. 
Perinatal asphyxia and sepsis are thought to be risk factors for the 
development of thrombosis, possibly related to some degree of dis­
seminated intravascular coagulation and hypoxic damage to vessel 
endothelium (6,37,38). We noted a high incidence of infection in our 
patients (62%). Therefore, we recommend prescribing antibiotics in 
neonates with thrombosis in an attempt to treat coexistent or prevent 
superimposed infection and possibly therapy failure. Because of the 
predominance of gram-positive strains (69%) small-spectrum anti­
biotics may be applied, unless blood cultures prove otherwise. Broad- 
spectrum antibiotics should only be given if necessary, because of the 
risk of roultiresistant strains.
A significantly higher birth weight and gestational age were found in 
neonates with catheter related central venous thrombosis when com-
In our opinion, of the conventional thrombolytic agents urokinase is pared to neonates without thrombosis in the presence of a central
the drug of choice in the neonatal period because of its single-step plas- venous catheter. These findings suggest that neonates with a higher
minogen activation, a more predictable dose-response relationship than birthweight and gestational age are at risk for developing catheter
other agents and its nonantigenicity in humans (6, 10). Streptokinase related central venous thrombosis. A relatively large proportion of
should not be used in the newborn because of risk of bleeding compli- neonates with a higher weight probably has perinatal asphyxia or
cations during prolonged use. Urokinase has a more selective action on sepsis, which may contribute to the development of thrombosis. An-
fibrin, and is therefore less dangerous. Recently developed thrombo- other possibility is that small thrombi may be overlooked in low birth
lytic agents such as recombinant single-chain urokinase plasminogen weight neonates because of the difficulty of performing echo Doppler
activator (r scu-PA) and recombinant tissue-type plasminogen activator cardiography, which therefore becomes less reliable in these infants.
(rt-PA) could also be applied in the newborn, however experience with Hemorrhagic complications during thrombolytic therapy occur in
these agents in neonates is limited (29-31). Moreover, a recent mul- about 5% of adult patients (29, 30). In neonates, hemorrhagic and 
ticenter trial in adults has reported a higher incidence of cerebral embolic complications are especially feared. In case reports using uro-
haemorrhage with the use of rt-PA (32). kinase for central venous thrombosis in neonates pulmonary embolism
In studies performed on adults the incidence of reperfusion of coro- has been reported in 2 of 29 neonates (7%) (14,16). Cereberal hemor-
nary arteries has been 60-70%, regardless of the agent used (29,30). In 
adults with catheter related central venous thrombosis, treatment with 
urokinase resulted in complete thrombolysis in 36 of 38 patients (95%) (8%).
rhage has been reported once in a patient with arterial thrombosis (39). 
We noted only mild peripheral hemorrhagic complications in 2 patients
(33). In the literature, 8 case reports describe the use of urokinase in In adults, approximately 10 to 20 percent of reperfused arteries
newborns, resulting in thrombolysis in 26 of 29 infants (90%) (12-19). develop recurrent thrombosis despite additional anticoagulant therapy 
In contrast, we could only achieve complete thrombolysis in 50% of our (29, 30). In the neonatal case-reports reviewed by these authors re­
patients, in spite of high dosages of urokinase, It seems likely that in current thrombosis occurred in 6 of 29 patients (21%) (12-19). In our 
neonates the results of thrombolytic therapy are less favourable than in study 4 patients developed recurrent thrombosis (28%), three despite
adults. Factors such as reduced levels of plasminogen, and higher levels 
of inhibitors of plasminogen activation have been thought to contribute 
to a decreased fibrinolytic activity in the newborn and an impaired re­
anticoagulant therapy. Of 9 residual thrombi after urokinase therapy 6 
(67%) resolved following additional anticoagulant therapy for
3 months, It is not clear whether these thrombi would have resolved
sponse to fibrinolytic therapy in newborns compared to adults (34-36). spontaneously without anticoagulant therapy. Patients with and without 
Investigators have suggested that the newborn may need up to 11 times residual thrombosis after urokinase therapy may benefit from addi-
the usual dosage of urokinase compared to adults (9). A recent in vitro 
study showed an evident resistance of newborn fibrin clots to all throm­
bolytic agents due to low levels of plasminogen. The degree of fibrino­
lysis could be increased to adult values by increasing plasminogen con­
centrations (35). These findings may explain the relative insensitivity to 
even high dosages of thrombolytic agents in newborn, which is also
tionai treatment with oral anticoagulants. The appropriate duration and 
dose of oral anticoagulants needs further investigation,
Prevention of catheter related central venous thrombosis is an im­
portant, yet unresolved, issue, A continuous infusion of low dose hepa­
rin has been shown to prolong catheter patency (40), but a significant 
reduction in catheter related central venous thrombosis has not been
illustrated by the minimal alterations in thrombin time and fibrinogen confirmed (8,41). Despite heparin prophylaxis in all patients with cen- 
Ievel during urokinase therapy (Fig. 2). It is possible that increasing the tral venous catheters we reported a rather high incidence o f  thrombosis 
concentration of plasminogen will enhance the clinical response to (6%). Hydrophilic polyurethane catheters seem to have the least throm-
thrombolytic therapy in newborns. However, in our patients the ad­
ministration of fresh frozen plasma did not enhance the success rate of 
urokinase therapy.
bogenic properties (42). However, prolonged use of hydrophilic poly­
urethane catheters did not lead to a significant reduction in the inci­
dence of thrombi when compared to prolonged use of polyvinyl 
Other factors that are less favourable for successful thrombolytic chloride catheters (43). It is possible that the abnormal coagulation and 
therapy are peripheral location of the thrombus, large thrombus size, fibrinolytic system in the newborn and conditions such as sepsis and
thrombus age more than 7 days and low plasminogen concentration 
(10). We noted that a lower incidence of successful thrombolysis in our
asphyxia are of greater importance in the etiology of catheter related 
thrombosis. Apart from limited use of central venous catheters, 
patients may have been related to some of these factors (Table 2), but especially in asphyxiated and septic newborns, ealry detection and
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appropriate treatment of catheter related central venous thrombosis 
remain of crucial importance.
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